Publications by authors named "K Philp"

Article Synopsis
  • - A study investigated if styrene, known to cause lung tumors in mice but not in rats, contributes to genotoxicity as a potential first step in tumor development.
  • - Transgenic mice were treated with varying doses of styrene for 28 days, and the frequency of mutations in lung and non-lung tissues was measured.
  • - Results showed no increase in mutations in treated mice, indicating that styrene is unlikely to act as a mutagen in vivo and does not initiate lung tumors in this model.
View Article and Find Full Text PDF

Seaweeds are potentially sustainable crops and are receiving significant interest because of their rich bioactive compound content; including fatty acids, polyphenols, carotenoids, and complex polysaccharides. However, there is little information on the in vivo effects on gut health of the polysaccharides and their low-molecular-weight derivatives. Herein, we describe the first investigation into the prebiotic potential of low-molecular-weight polysaccharides (LMWPs) derived from alginate and agar in order to validate their in vivo efficacy.

View Article and Find Full Text PDF

Many factors, including the demonstrator's sex, status, and familiarity, shape the nature and magnitude of social learning. Given the important role of pair bonds in socially-monogamous animals, we predicted that these intimate relationships would promote the use of social information, and tested this hypothesis in zebra finches (Taeniopygia guttata). Observer birds witnessed either their mate or another familiar, opposite-sex bird eat from one, but not a second novel food source, before being allowed to feed from both food sources themselves.

View Article and Find Full Text PDF

Background And Purpose: Fostamatinib is an inhibitor of spleen tyrosine kinase (TK). In patients, fostamatinib treatment was associated with increased BP. Some TK inhibitors cause BP elevation, by inhibiting the VEGF receptor 2 (VEGFR2).

View Article and Find Full Text PDF

Despite rigorous preclinical and clinical safety evaluation, adverse cardiac effects remain a leading cause of drug attrition and post-approval drug withdrawal. A number of cardiovascular screens exist within preclinical development. These screens do not, however, provide a thorough cardiac liability profile and, in many cases, are not preventing the progression of high risk compounds.

View Article and Find Full Text PDF